Research ExplorerPublicationsStereotactic body radiotherapy (SBRT) for multiple pulmonary...

Stereotactic body radiotherapy (SBRT) for multiple pulmonary oligometastases

Standard

Stereotactic body radiotherapy (SBRT) for multiple pulmonary oligometastases : Analysis of number and timing of repeat SBRT as impact factors on treatment safety and efficacy. / Klement, R J; Hoerner-Rieber, J; Adebahr, S; Andratschke, N; Blanck, O; Boda-Heggemann, J; Duma, M; Eble, M J; Eich, H C; Flentje, M; Gerum, S; Hass, P; Henkenberens, C; Hildebrandt, G; Imhoff, D; Kahl, K H; Klass, N D; Krempien, R; Lohaus, F; Petersen, C; Schrade, E; Wendt, T G; Wittig, A; Guckenberger, M.

In: RADIOTHER ONCOL, Vol. 127, No. 2, 05.2018, p. 246-252.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Klement, RJ, Hoerner-Rieber, J, Adebahr, S, Andratschke, N, Blanck, O, Boda-Heggemann, J, Duma, M, Eble, MJ, Eich, HC, Flentje, M, Gerum, S, Hass, P, Henkenberens, C, Hildebrandt, G, Imhoff, D, Kahl, KH, Klass, ND, Krempien, R, Lohaus, F, Petersen, C, Schrade, E, Wendt, TG, Wittig, A & Guckenberger, M 2018, 'Stereotactic body radiotherapy (SBRT) for multiple pulmonary oligometastases: Analysis of number and timing of repeat SBRT as impact factors on treatment safety and efficacy', RADIOTHER ONCOL, vol. 127, no. 2, pp. 246-252. https://doi.org/10.1016/j.radonc.2018.02.016

APA

Klement, R. J., Hoerner-Rieber, J., Adebahr, S., Andratschke, N., Blanck, O., Boda-Heggemann, J., Duma, M., Eble, M. J., Eich, H. C., Flentje, M., Gerum, S., Hass, P., Henkenberens, C., Hildebrandt, G., Imhoff, D., Kahl, K. H., Klass, N. D., Krempien, R., Lohaus, F., ... Guckenberger, M. (2018). Stereotactic body radiotherapy (SBRT) for multiple pulmonary oligometastases: Analysis of number and timing of repeat SBRT as impact factors on treatment safety and efficacy. RADIOTHER ONCOL, 127(2), 246-252. https://doi.org/10.1016/j.radonc.2018.02.016

Vancouver

Klement RJ, Hoerner-Rieber J, Adebahr S, Andratschke N, Blanck O, Boda-Heggemann J et al. Stereotactic body radiotherapy (SBRT) for multiple pulmonary oligometastases: Analysis of number and timing of repeat SBRT as impact factors on treatment safety and efficacy. RADIOTHER ONCOL. 2018 May;127(2):246-252. https://doi.org/10.1016/j.radonc.2018.02.016

Bibtex

@article{c9afa2185fce4a55919f7b786e14e55e,
title = "Stereotactic body radiotherapy (SBRT) for multiple pulmonary oligometastases: Analysis of number and timing of repeat SBRT as impact factors on treatment safety and efficacy",
abstract = "BACKGROUND: Stereotactic body radiotherapy (SBRT) for oligometastatic disease is characterized by an excellent safety profile; however, experiences are mostly based on treatment of one single metastasis. It was the aim of this study to evaluate safety and efficacy of SBRT for multiple pulmonary metastases.PATIENTS AND METHODS: This study is based on a retrospective database of the DEGRO stereotactic working group, consisting of 637 patients with 858 treatments. Cox regression and logistic regression were used to analyze the association between the number of SBRT treatments or the number and the timing of repeat SBRT courses with overall survival (OS) and the risk of early death.RESULTS: Out of 637 patients, 145 patients were treated for multiple pulmonary metastases; 88 patients received all SBRT treatments within one month whereas 57 patients were treated with repeat SBRT separated by at least one month. Median OS for the total patient population was 23.5 months and OS was not significantly influenced by the overall number of SBRT treatments or the number and timing of repeat SBRT courses. The risk of early death within 3 and 6 months was not increased in patients treated with multiple SBRT treatments, and no grade 4 or grade 5 toxicity was observed in these patients.CONCLUSIONS: In appropriately selected patients, synchronous SBRT for multiple pulmonary oligometastases and repeat SBRT may have a comparable safety and efficacy profile compared to SBRT for one single oligometastasis.",
keywords = "Adolescent, Adult, Aged, Aged, 80 and over, Child, Disease-Free Survival, Female, Humans, Lung Neoplasms/radiotherapy, Male, Middle Aged, Radiosurgery/adverse effects, Retrospective Studies, Treatment Outcome, Young Adult",
author = "Klement, {R J} and J Hoerner-Rieber and S Adebahr and N Andratschke and O Blanck and J Boda-Heggemann and M Duma and Eble, {M J} and Eich, {H C} and M Flentje and S Gerum and P Hass and C Henkenberens and G Hildebrandt and D Imhoff and Kahl, {K H} and Klass, {N D} and R Krempien and F Lohaus and C Petersen and E Schrade and Wendt, {T G} and A Wittig and M Guckenberger",
note = "Copyright {\textcopyright} 2018 Elsevier B.V. All rights reserved.",
year = "2018",
month = may,
doi = "10.1016/j.radonc.2018.02.016",
language = "English",
volume = "127",
pages = "246--252",
journal = "RADIOTHER ONCOL",
issn = "0167-8140",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

RIS

TY - JOUR

T1 - Stereotactic body radiotherapy (SBRT) for multiple pulmonary oligometastases

T2 - Analysis of number and timing of repeat SBRT as impact factors on treatment safety and efficacy

AU - Klement, R J

AU - Hoerner-Rieber, J

AU - Adebahr, S

AU - Andratschke, N

AU - Blanck, O

AU - Boda-Heggemann, J

AU - Duma, M

AU - Eble, M J

AU - Eich, H C

AU - Flentje, M

AU - Gerum, S

AU - Hass, P

AU - Henkenberens, C

AU - Hildebrandt, G

AU - Imhoff, D

AU - Kahl, K H

AU - Klass, N D

AU - Krempien, R

AU - Lohaus, F

AU - Petersen, C

AU - Schrade, E

AU - Wendt, T G

AU - Wittig, A

AU - Guckenberger, M

N1 - Copyright © 2018 Elsevier B.V. All rights reserved.

PY - 2018/5

Y1 - 2018/5

N2 - BACKGROUND: Stereotactic body radiotherapy (SBRT) for oligometastatic disease is characterized by an excellent safety profile; however, experiences are mostly based on treatment of one single metastasis. It was the aim of this study to evaluate safety and efficacy of SBRT for multiple pulmonary metastases.PATIENTS AND METHODS: This study is based on a retrospective database of the DEGRO stereotactic working group, consisting of 637 patients with 858 treatments. Cox regression and logistic regression were used to analyze the association between the number of SBRT treatments or the number and the timing of repeat SBRT courses with overall survival (OS) and the risk of early death.RESULTS: Out of 637 patients, 145 patients were treated for multiple pulmonary metastases; 88 patients received all SBRT treatments within one month whereas 57 patients were treated with repeat SBRT separated by at least one month. Median OS for the total patient population was 23.5 months and OS was not significantly influenced by the overall number of SBRT treatments or the number and timing of repeat SBRT courses. The risk of early death within 3 and 6 months was not increased in patients treated with multiple SBRT treatments, and no grade 4 or grade 5 toxicity was observed in these patients.CONCLUSIONS: In appropriately selected patients, synchronous SBRT for multiple pulmonary oligometastases and repeat SBRT may have a comparable safety and efficacy profile compared to SBRT for one single oligometastasis.

AB - BACKGROUND: Stereotactic body radiotherapy (SBRT) for oligometastatic disease is characterized by an excellent safety profile; however, experiences are mostly based on treatment of one single metastasis. It was the aim of this study to evaluate safety and efficacy of SBRT for multiple pulmonary metastases.PATIENTS AND METHODS: This study is based on a retrospective database of the DEGRO stereotactic working group, consisting of 637 patients with 858 treatments. Cox regression and logistic regression were used to analyze the association between the number of SBRT treatments or the number and the timing of repeat SBRT courses with overall survival (OS) and the risk of early death.RESULTS: Out of 637 patients, 145 patients were treated for multiple pulmonary metastases; 88 patients received all SBRT treatments within one month whereas 57 patients were treated with repeat SBRT separated by at least one month. Median OS for the total patient population was 23.5 months and OS was not significantly influenced by the overall number of SBRT treatments or the number and timing of repeat SBRT courses. The risk of early death within 3 and 6 months was not increased in patients treated with multiple SBRT treatments, and no grade 4 or grade 5 toxicity was observed in these patients.CONCLUSIONS: In appropriately selected patients, synchronous SBRT for multiple pulmonary oligometastases and repeat SBRT may have a comparable safety and efficacy profile compared to SBRT for one single oligometastasis.

KW - Adolescent

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Child

KW - Disease-Free Survival

KW - Female

KW - Humans

KW - Lung Neoplasms/radiotherapy

KW - Male

KW - Middle Aged

KW - Radiosurgery/adverse effects

KW - Retrospective Studies

KW - Treatment Outcome

KW - Young Adult

U2 - 10.1016/j.radonc.2018.02.016

DO - 10.1016/j.radonc.2018.02.016

M3 - SCORING: Journal article

C2 - 29510865

VL - 127

SP - 246

EP - 252

JO - RADIOTHER ONCOL

JF - RADIOTHER ONCOL

SN - 0167-8140

IS - 2

ER -